Cancer risk assessment and treatment management software developer CancerIQ plans to partner with Azra AI to support lung cancer screening by blending risk-based patient identification with AI-powered low-dose CT (LDCT) follow-up.
CancerIQ helps radiology departments and cancer centers identify patients who may benefit from lung cancer screening, assess individualized risk, educate patients, and guide appropriate LDCT scheduling. Azra AI's enterprise platform uses AI to help radiology teams to track actionable findings, prioritize follow-up, and manage patients, according to the two firms.
